Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression
Lung cancer is the most typical form of cancer that results in death worldwide. Patients with non-small cell lung cancer (NSCLC) have an around 15% survival rate despite of advancement in cancer treatment. This study aimed to evaluate the combined effect of celecoxib and bevacizumab on NSCLC using A...
Spremljeno u:
| Glavni autori: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
University of Karachi
2023-03-01
|
| Serija: | Pakistan Journal of Pharmaceutical Sciences |
| Online pristup: | https://pjps.pk/single-article?id=cmrgqbeky01zoqsr2bs1a0su9 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|